Jpmorgan Chase & CO Exact Sciences Corp Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
A detailed history of Jpmorgan Chase & CO transactions in Exact Sciences Corp stock. As of the latest transaction made, Jpmorgan Chase & CO holds 12,384,516 shares of EXAS stock, worth $512 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
12,384,516
Previous 16,690,808
25.8%
Holding current value
$512 Million
Previous $1.23 Billion
30.73%
% of portfolio
0.08%
Previous 0.13%
Shares
12 transactions
Others Institutions Holding EXAS
# of Institutions
699Shares Held
160MCall Options Held
5.84MPut Options Held
2.58M-
Vanguard Group Inc Valley Forge, PA17.7MShares$734 Million0.02% of portfolio
-
Capital World Investors Los Angeles, CA13MShares$539 Million0.15% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$471 Million0.02% of portfolio
-
Wellington Management Group LLP Boston, MA10.7MShares$442 Million0.13% of portfolio
-
State Street Corp Boston, MA5.09MShares$211 Million0.02% of portfolio
About EXACT SCIENCES CORP
- Ticker EXAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 176,960,000
- Market Cap $7.32B
- Description
- Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...